Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Diurnal Group Plc LSE:DNL London Ordinary Share GB00BDB6Q760 ORD GBP0.05
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 31.00 27,100 07:33:06
Bid Price Offer Price High Price Low Price Open Price
30.00 32.00 31.00 31.00 31.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.04 -14.40 -19.70 38
Last Trade Time Trade Type Trade Size Trade Price Currency
15:06:46 O 25,000 31.00 GBX

Diurnal (DNL) Latest News

More Diurnal News
Diurnal Takeover Rumours

Diurnal (DNL) Discussions and Chat

Diurnal Forums and Chat

Date Time Title Posts
22/5/202011:40Diurnal (MC Ј25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP342
29/7/201910:46Diurnal Group plc201

Add a New Thread

Diurnal (DNL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-05-26 14:06:4731.0025,0007,750.00O
2020-05-26 13:06:5830.0010030.00O
2020-05-26 11:24:5731.002,000620.00O
View all Diurnal trades in real-time

Diurnal (DNL) Top Chat Posts

DateSubject
26/5/2020
09:20
Diurnal Daily Update: Diurnal Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DNL. The last closing price for Diurnal was 31p.
Diurnal Group Plc has a 4 week average price of 28p and a 12 week average price of 21p.
The 1 year high share price is 47p while the 1 year low share price is currently 21p.
There are currently 121,633,387 shares in issue and the average daily traded volume is 90,302 shares. The market capitalisation of Diurnal Group Plc is £37,706,349.97.
27/3/2020
07:47
hulk2004: It’s not about today, share price will be what it will be in these uncertain times, share price in 6 months will be in the pounds if all goes well.
17/3/2020
14:49
qs99: thanks timbo..... DNL share price nuts given just raised £11m!
06/3/2020
18:47
weatherman: OK - so £7m was a minimum - £11m and 40% it is. The market cap has gone from £29m to above £40m, and share price has gone up 0p.
28/2/2020
07:41
optrade: DIURNAL GROUP … and more to come (news flow) the share price is still languishing well below valuations determined by peer group and DCF (344p) HTTP://ow.ly/KzNI50yycoW
13/2/2020
07:33
ih_116147: GREAT News out today ..NDA accepted by FDA and the Drug could be approved in Q3 .. Still the CHEAPEST and most attractive small cap Biotech in UK . A potential 10 Bagger here Diurnal : US FDA Accepts NDA Application for Alkindi hxxps://www.marketscreener.com/DIURNAL-GROUP-PLC-25531374/news/Diurnal-US-FDA-Accepts-NDA-Application-for-Alkindi-29990468/ Application seeks approval of Alkindi® Sprinkle as a replacement therapy of adrenal insufficiency in infants, children and adolescents NDA could potentially be approved in Q3 2020 Diurnal (DNL) Market Cap £23 M Price: 28p New Presentation hxxps://www.diurnal.co.uk/media/hxxps://www.diurnal.co.uk/media/36790/interim-results-presentation-february-2020-pp.pdf/full-year-results-presentationyear-ended-30-june-2019-pp-v2.pdf DCF valuation of 202p per share https://www.hardmanandco.com/wp-content/uploads/2019/11/DNL-2019-results-5-November-2019.pdf Investment summary:Alkindi, a cortisol replacement therapy designed for children under 18 years of age, is DNL’s first product on the market. It is expected to be followed by Chronocort for adults – a larger market – which now has a clear pathway for regulatory approval in both Europe and the US. Despite this, the share price is still languishing well below valuations determined by peer group and DCF (202p) analyses Upcoming Catalysts: MAA-Acceptance for Chronocort in February/March 2020 Alkindi approval in Israel expected in 2Q 2020 Alkindi approval in Australien expected in 2Q 2020 US-Partnership for Alkindi & Chronocort expected in 1H 2020 Alkindi & Chronocort Partnership for Asia für Japan und China US-Approval for Alkindi expected in 4Q 2020 EU Approval for Chronocort expected in 4Q/1Q 2020/21 $88m market opportunity (Europe and US) for Paediatric AI (inc CAH) $351m market opportunity (Europe and US) for Congenital Adrenal Hyperplasia $2,767m market opportunity (Europe and US) for Adrenal Insufficiency
10/1/2020
15:48
qs99: Interesting to see the awards "Achieving a target share price of 89 pence for a one-month rolling period during the 5 years following grant".....decent upside then to achieve before award or am I mis-reading that in rush!
20/11/2019
08:03
ih_615088: Great News out and much more to come Diurnal (DNL) Price:30p --Market Cap £26 M --Cash £9 M--MEGA milestones expected within 4 weeks = 300-500% GEM Approaching anumber of near-term milestones....5 November 2019 https://www.hardmanandco.com/wp-content/uploads/2019/11/DNL-2019-results-5-November-2019.pdf DITEST™(Hypogonadism) study readout Q4 2019 Alkindi® US NDA submission to the FDA(paediatric AI,including CAH)Q4 2019 Chronocort® European regulatory submission to the EMA(CAH)Q4 2019 Conclude US partnering discussions for Alkindi®(Chronocort®)H1 2020 Presentation hxxps://www.diurnal.co.uk/media/36783/full-year-results-presentationyear-ended-30-june-2019-pp-v2.pdf
24/7/2019
15:24
frrinvest: TO BE PRECISE, BROKER PRICE TARGET £2.25 NOW! https://www.hardmanandco.com/wp-content/uploads/2019/04/DNL-Interim-update-25-April-2019.pdf from above link ... Based on our clearly stated assumptions, the net present value of the cashflows that could be generated from DNL’s first two products alone equates to £248m. Riskadjustment to take account of their different stages of development in different territories reduces this to £139m, or 225p per share. Conclusion Whichever valuation method is used, there appears to be significant upside potential for the stock. However, the current share price remains dogged by the unexpected outcome of the Phase III trial in Europe with Chronocort, despite the fact that the EMA has seen the data, and paved the way for regulatory submission later this year. The share price also reflects the fact that the company will require more capitalin 2019 in the absence of any significant licensing deals. DNL’s US competitors, shown in the competitive analysis above, are cash-rich and looking for complementary endocrine products. Therefore, failure of the UK market to recognise the full potential value could see the emergence of a predator.
22/7/2019
10:20
frrinvest: https://www.hardmanandco.com/wp-content/uploads/2019/04/DNL-Interim-update-25-April-2019.pdf from above link ... Based on our clearly stated assumptions, the net present value of the cashflows that could be generated from DNL’s first two products alone equates to £248m. Riskadjustment to take account of their different stages of development in different territories reduces this to £139m, or 225p per share. Conclusion Whichever valuation method is used, there appears to be significant upside potential for the stock. However, the current share price remains dogged by the unexpected outcome of the Phase III trial in Europe with Chronocort, despite the fact that the EMA has seen the data, and paved the way for regulatory submission later this year. The share price also reflects the fact that the company will require more capitalin 2019 in the absence of any significant licensing deals. DNL’s US competitors, shown in the competitive analysis above, are cash-rich and looking for complementary endocrine products. Therefore, failure of the UK market to recognise the full potential value could see the emergence of a predator.
25/4/2019
08:52
costax1654x: From LSE: 225p Valuation!I must say this report sums up the situation very well, massive upside from here - 765% to be precise (225p target vs 26p current). https://www.hardmanandco.com/wp-content/uploads/2019/04/DNL-Interim-update-25-April-2019.pdf"Based on our clearly stated assumptions, the net present value of the cashflows that could be generated from DNL's first two products alone equates to £248m. Risk- adjustment to take account of their different stages of development in different territories reduces this to £139m, or 225p per share.""Whichever valuation method is used, there appears to be significant upside potential for the stock. However, the current share price remains dogged by the unexpected outcome of the Phase III trial in Europe with Chronocort, despite the fact that the EMA has seen the data, and paved the way for a regulatory submission later this year. The share price also reflects the fact that the company will require more capital in 2019 in the absence of any significant licensing deals. DNL's US competitors, shown in the competitive analysis above, are cash-rich and looking for complementary endocrine products. Therefore, failure of the UK market to recognise the full potential value could see the emergence of a predator."
Diurnal share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
DNL
Diurnal
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200527 04:21:10